PD Dr. Hans Jürgen Rech

Einrichtungen, die zum Universitätsklinikum Erlangen gehören Medizinische Fakultät Department of Medicine 3 – Rheumatology and Immunology

Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial (2021) Venhoff N, Schmidt W, Bergner R, Rech J, Unger L, Tony HP, Mendelson M, et al. Conference contribution Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials (2021) Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa AC, Combe B, Rech J, et al. Journal article Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study (2021) Schönau V, Roth J, Tascilar K, Corte G, Manger B, Rech J, Schmidt D, et al. Journal article High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study (2021) Behrens F, Rech J, Thaci D, Zinke S, Rothnie KJ, (Oefner) Daamen C, Leipe J Journal article LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)-30-MONTH DATA FROM THE RELIANCE REGISTRY (2021) Kuemmerle-Deschner JB, Kortus-Goetze B, Oommen P, Janda A, Rech J, Kallinich T, Weller-Heinemann F, et al. Conference contribution TREATMENT TAPERING AND WITHDRAWAL IN RHEUMATOID ARTHRITIS WITH STABLE REMISSION - FINAL ANALYSIS OF THE RETRO STUDY (2021) Hagen M, Tascilar K, Reiser M, Valor L, Haschka J, Kleyer A, Hueber A, et al. Conference contribution SPATIOTEMPORAL DYNAMICS OF BONE LOSS BEFORE AND AFTER THE ONSET OF RHEUMATOID ARTHRITIS (2021) Tascilar K, Simon D, Liphardt AM, Meinderink T, Bayat S, Rech J, Hueber A, et al. Conference contribution ASSOCIATION OF ANTI-CITRULLINATED PROTEIN ANTIBODIES OF IgA SUBCLASSES WITH SUSTAINED REMISSION AND FLARE IN RHEUMATOID ARTHRITIS (2021) Sokolova M, Rech J, Hagen M, Schett G, Steffen U Conference contribution PATIENTS AT RISK FOR RA SHOW THE SAME AMOUNT OF ACUTE SOLUBLE CARTILAGE DEGRADATION MARKERS AFTER PHYSICAL ACTIVITY COMPARED TO PATIENTS WITH ESTABLISHED RA (2021) Bleckwedel-Rolack LLK, Tascilar K, Nees V, Hühne J, Hueber A, Rech J, Schett G, et al. Conference contribution Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain – Study protocol for a randomized double-blind controlled study (2021) Schenker H, Tascilar K, Konerth L, Sergeeva M, Prade J, Strobelt S, Kleyer A, et al. Journal article